INTRODUCTION: Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. DISCUSSION AND CONCLUSION: Our group has developed MRI techniques to detect individual amyloid plaques in AD transgenic mouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of AD transgenic mice. This short review briefly discusses our progress in these areas.
INTRODUCTION:Alzheimer's disease (AD) is the most prevalent neurological condition affecting industrialized nations and will rapidly become a healthcare crisis as the population ages. Currently, the post-mortem histological observation of amyloid plaques and neurofibrillary tangles is the only definitive diagnosis available for AD. A pre-mortem biological or physiological marker specific for AD used in conjunction with current neurological and memory testing could add a great deal of confidence to the diagnosis of AD and potentially allow therapeutic intervention much earlier in the disease process. DISCUSSION AND CONCLUSION: Our group has developed MRI techniques to detect individual amyloid plaques in ADtransgenicmouse brain in vivo. We are also developing contrast-enhancing agents to increase the specificity of detection of amyloid plaques. Such in vivo imaging of amyloid plaques will also allow the evaluation of anti-amyloid therapies being developed by the pharmaceutical industry in pre-clinical trials of ADtransgenic mice. This short review briefly discusses our progress in these areas.
Authors: Joseph F Poduslo; Muthu Ramakrishnan; Silvina S Holasek; Marina Ramirez-Alvarado; Karunya K Kandimalla; Emily J Gilles; Geoffry L Curran; Thomas M Wengenack Journal: J Neurochem Date: 2007-07 Impact factor: 5.372
Authors: Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio Journal: Am J Geriatr Psychiatry Date: 2002 Jan-Feb Impact factor: 4.105
Authors: L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff Journal: Nat Med Date: 1998-01 Impact factor: 53.440
Authors: J E Maggio; E R Stimson; J R Ghilardi; C J Allen; C E Dahl; D C Whitcomb; S R Vigna; H V Vinters; M E Labenski; P W Mantyh Journal: Proc Natl Acad Sci U S A Date: 1992-06-15 Impact factor: 11.205
Authors: Joseph F Poduslo; Geoffry L Curran; Jane A Peterson; Daniel J McCormick; Abdul H Fauq; Murad A Khan; Thomas M Wengenack Journal: Biochemistry Date: 2004-05-25 Impact factor: 3.162
Authors: Youssef Zaim Wadghiri; Einar M Sigurdsson; Marcin Sadowski; James I Elliott; Yongsheng Li; Henrieta Scholtzova; Cheuk Ying Tang; Gilbert Aguinaldo; Miguel Pappolla; Karen Duff; Thomas Wisniewski; Daniel H Turnbull Journal: Magn Reson Med Date: 2003-08 Impact factor: 4.668
Authors: Nicolaas P L G Verhoeff; Alan A Wilson; Shinichiro Takeshita; Liat Trop; Doug Hussey; Kernjit Singh; Hank F Kung; Mei-Ping Kung; Sylvain Houle Journal: Am J Geriatr Psychiatry Date: 2004 Nov-Dec Impact factor: 4.105
Authors: Paul A Adlard; Bob A Tran; David I Finkelstein; Patricia M Desmond; Leigh A Johnston; Ashley I Bush; Gary F Egan Journal: Front Neurosci Date: 2014-10-31 Impact factor: 4.677